Cargando…
CART cell therapy for prostate cancer: status and promise
In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly di...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322708/ https://www.ncbi.nlm.nih.gov/pubmed/30655675 http://dx.doi.org/10.2147/OTT.S185556 |
_version_ | 1783385638000656384 |
---|---|
author | Yu, Haiyuan Pan, Jun Guo, Zhicheng Yang, Chunhua Mao, Lijun |
author_facet | Yu, Haiyuan Pan, Jun Guo, Zhicheng Yang, Chunhua Mao, Lijun |
author_sort | Yu, Haiyuan |
collection | PubMed |
description | In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly different from traditional T cells. In spite of the progress of CART-T technology in the treatment of lymphoma, leukemia, and other blood system tumor, there are still many difficulties in the treatment of solid tumors by CAR-T technology. In this review, we will make a brief summary of the present situation of CAR-T cells in the treatment of prostate cancer, and discuss the promise of the application of this technology to prostate cancer therapy. |
format | Online Article Text |
id | pubmed-6322708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63227082019-01-17 CART cell therapy for prostate cancer: status and promise Yu, Haiyuan Pan, Jun Guo, Zhicheng Yang, Chunhua Mao, Lijun Onco Targets Ther Review In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly different from traditional T cells. In spite of the progress of CART-T technology in the treatment of lymphoma, leukemia, and other blood system tumor, there are still many difficulties in the treatment of solid tumors by CAR-T technology. In this review, we will make a brief summary of the present situation of CAR-T cells in the treatment of prostate cancer, and discuss the promise of the application of this technology to prostate cancer therapy. Dove Medical Press 2019-01-03 /pmc/articles/PMC6322708/ /pubmed/30655675 http://dx.doi.org/10.2147/OTT.S185556 Text en © 2019 Yu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Yu, Haiyuan Pan, Jun Guo, Zhicheng Yang, Chunhua Mao, Lijun CART cell therapy for prostate cancer: status and promise |
title | CART cell therapy for prostate cancer: status and promise |
title_full | CART cell therapy for prostate cancer: status and promise |
title_fullStr | CART cell therapy for prostate cancer: status and promise |
title_full_unstemmed | CART cell therapy for prostate cancer: status and promise |
title_short | CART cell therapy for prostate cancer: status and promise |
title_sort | cart cell therapy for prostate cancer: status and promise |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322708/ https://www.ncbi.nlm.nih.gov/pubmed/30655675 http://dx.doi.org/10.2147/OTT.S185556 |
work_keys_str_mv | AT yuhaiyuan cartcelltherapyforprostatecancerstatusandpromise AT panjun cartcelltherapyforprostatecancerstatusandpromise AT guozhicheng cartcelltherapyforprostatecancerstatusandpromise AT yangchunhua cartcelltherapyforprostatecancerstatusandpromise AT maolijun cartcelltherapyforprostatecancerstatusandpromise |